Stock Market & Financial Investment News

News Breaks February 12, 2013 07:06 EDT BMY Bristol-Myers enters collaboration agreement with Reckitt Beckiser Group Bristol-Myers announced it has entered into a three-year collaboration agreement with Reckitt Benckiser Group for several of its over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil. Under the terms of the collaboration agreement, Reckitt Benckiser will pay Bristol-Myers Squibb an upfront payment in the amount of $438M for the exclusive rights to sell, distribute and market the following medicines for a three-year period: Picot, an antacid, Tempra, a pain reliever and fever reducer, Micostatin, an antifungal, and Graneodin, a cough and cold medicine, sold primarily in Mexico; and Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and Naldecon, a cold and flu symptoms treatment, sold primarily in Brazil. During the collaboration term, Bristol-Myers Squibb will retain responsibility for manufacturing all of the products covered by the collaboration, and Reckitt Benckiser will purchase products from Bristol-Myers Squibb and pay royalties on product sales during the term of the collaboration. Reckitt Benckiser will also pay to Bristol-Myers Squibb an option fee in the amount of $44M for the right to purchase these products outright at the end of the three-year term, acquiring the sales, marketing, and distribution rights, along with assets related to the products, including the trademarks, remaining inventories, and certain other assets. News For BMY From The Last 14 Days Check below for free stories on BMY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 05:43 EDT BMY AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza Subscribe for More Information June 17, 2013 07:28 EDT BMY Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 09:03 EDT BMY Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. 08:02 EDT BMY Bristol-Myers, Simcere enter Orencia pact for China Subscribe for More Information June 13, 2013 11:02 EDT BMY Leerink's major pharma analyst holds an analyst/Industry conference call Subscribe for More Information June 12, 2013 13:15 EDT BMY Bristol-Myers, AstraZeneca issue statement on review of some therapies Subscribe for More Information June 11, 2013 18:09 EDT BMY Orencia trial data shows efficacy rate comparable to Humira Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. 08:01 EDT BMY Leerink's major pharma and biotech analysts hold a conference call Subscribe for More Information June 7, 2013 13:49 EDT BMY Bristol-Myers volatility elevated as shares pullback from 11-year high Subscribe for More Information June 6, 2013 11:04 EDT BMY Bristol-Myers says Health Canada expands Abilify indications Abilify has received an additional approval from Health Canada as an adjunct, or add-on, treatment to antidepressants for the treatment of major depressive disorder in adults who had an inadequate response to prior antidepressant treatments during the current episode. Sign up for a free trial to see the rest of the stories you've been missing.